Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 in compensated cirrhosis with clinically significant portal hypertension
2021-001285-38Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avenciguat in Portal Hypertension (PH) and Cirrhosis (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage change in hepatic venous pressure gradient from baseline at 24 weeks. Started Aug 2021; status: terminated.
02
Drugs
avenciguat
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on 2021-001285-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001285-38.